Search Results

Positive topline results from the Phase 3 pivotal study, BRIO-II, evaluating BRIMOCHOL™ PF, a preservative-free ophthalmic solution for the treatment of presbyopia, have been announced by biotech company Tenpoint Therapeutics.

As we eagerly await the innovations and breakthroughs that 2025 promises ophthalmlology, we reached out to some of our esteemed editorial board members to share their insights.

As 2024 draws to a close, we’re celebrating a remarkable year of content.

The American Academy of Ophthalmology (AAO) 2024 meeting in Chicago showcased many advancements in retinal research that show promise for the future.

We have seen plenty of innovation in ophthalmology, with researchers and clinicians making significant strides in how eye conditions are treated and managed. From improving drug delivery methods to harnessing the potential of gene and stem cell therapies, 2024 has been a year of promising progress across multiple areas. As we edge closer to 2025, we are eager to see what advancements will further improve vision and eye care. To envision what lies ahead, we turn to our expert editorial board to share their insights on the developments shaping the future of ophthalmology: